|
Market Closed -
Nasdaq
16:00:00 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 0.5451 USD | -2.21% |
|
+4.21% | -29.85% |
Company Valuation: Citius Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 296.3 | 176.8 | 108.7 | 90.47 | 21.1 | 14.96 | - | - |
| Change | - | -40.33% | -38.51% | -16.79% | -76.68% | -29.06% | - | - |
| Enterprise Value (EV) | 296.3 | 176.8 | 108.7 | 90.47 | 21.1 | 14.96 | 14.96 | 14.96 |
| Change | - | -40.33% | -38.51% | -16.79% | -76.68% | -29.06% | 0% | 0% |
| P/E | -8.83x | -5.26x | -3.11x | -2.1x | -0.37x | -0.27x | -0.38x | -0.81x |
| PBR | - | 1.72x | 1.2x | - | - | - | - | - |
| PEG | - | - | 0.72x | -0.25x | 0x | 0x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - | 1.49x | 0.73x | 0.3x |
| EV / Revenue | - | - | - | - | - | 1.49x | 0.73x | 0.3x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -0.23x | -0.36x | -0.67x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -5.75 | -5.75 | -5.5 | -5.97 | -3.38 | -2.03 | -1.44 | -0.67 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | 10.05 | 20.52 | 50.68 |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -23.53 | -33.32 | -36.73 | -42 | -38.53 | -64.14 | -41.79 | -22.28 |
| Net income 1 | -24.51 | -33.64 | -33.69 | -40.19 | -37.43 | -60.7 | -41.79 | -22.28 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 50.7500 | 30.2500 | 17.1100 | 12.5150 | 1.2400 | 0.5451 | 0.5451 | 0.5451 |
| Nbr of stocks (in thousands) | 5,839 | 5,845 | 6,354 | 7,229 | 17,012 | 27,453 | - | - |
| Announcement Date | 12/15/21 | 12/22/22 | 12/29/23 | 12/27/24 | 12/23/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.27x | - | - | - | 14.96M | |
| 17.43x | 6.68x | 12.81x | 1.71% | 66.7B | |
| 30.07x | 8.27x | 26.77x | 0.07% | 56.88B | |
| 38.45x | 6.84x | 20.45x | 0.85% | 56.53B | |
| 46.55x | 6.14x | 30.16x | -.--% | 46.49B | |
| 35.48x | 3.35x | 14.48x | -.--% | 44.8B | |
| -22.71x | 62.58x | -21.48x | -.--% | 41.59B | |
| 35.87x | 8.84x | 23.03x | 0.37% | 35.35B | |
| 41.46x | 8.08x | 26.8x | -.--% | 33.29B | |
| -69.81x | 13.21x | -71.01x | -.--% | 25.1B | |
| Average | 15.25x | 13.78x | 6.89x | 0.33% | 40.67B | |
| Weighted average by Cap. | 21.52x | 12.92x | 11.34x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- CTXR Stock
- Valuation Citius Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
